Healix Collaborative Research at ACG 2021

Healix is proud to participate in collaborative research with our clients at the 2021 American College of Gastroenterology (ACG) Annual Meeting. While attending the conference, please visit the following Healix poster presentations on Monday, October 25 from 10:30 AM until 4:15 PM. Presenting authors will be available at the posters from 1:00 PM until 2:15 PM. 

(#P1621) Payor-Mandated Non-Medical Switching from Infliximab to Biosimilar Creates Dosing Delays 

Samantha A. Mehta, PharmD1; Timothy E. Ritter, MD2; Christopher Fernandes3; Siri Tummala3; Brooklin C. Smith4; Lucinda J. Van Anglen, PharmD1. 

1Healix Infusion Therapy, LLC, Sugar Land, TX, 2GI Alliance, Southlake, TX, 3TCU and UNTHSC School of Medicine, 4Kansas City University Medicine and Biosciences. 

(#P1622) Infusible Biologics in Gastroenterology Physician Clinics Were Not Impacted by the COVID-19 Pandemic 

Timothy E. Ritter, MD1; Harry E. Sarles, MD2; Samantha A. Mehta, PharmD3; Siri Tummala4; Brooklin C. Smith5; Christopher C. Fernandes4; Lucinda J. Van Anglen, PharmD3. 

1GI Alliance, Southlake, TX, 2Digestive Health Associates of Texas, Richardson, TX, 3Healix Infusion Therapy, LLC, Sugar Land, TX, 4TCU and UNTHSC School of Medicine, 5Kansas City University Medicine and Biosciences. 


View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.